Georgia's Online Cancer Information Center

Find A Clinical Trial

REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

Status
Active
Cancer Type
Bile Duct Cancer
Liver Cancer / Hepatoblastoma
Solid Tumor
Unknown Primary
Trial Phase
Phase I
Phase II
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCT ID
NCT04526106
Protocol IDs
RLY-4008-101 (primary)
NCI-2020-06870
Study Sponsor
Relay Therapeutics, Inc.

Summary

This is a Phase 1/2, open-label, FIH study designed to evaluate the safety, tolerability,
pharmacokinetics (PK), pharmacodynamics (PDy), and antineoplastic activity of RLY-4008, a
potent and highly selective FGFR2 inhibitor, in patients with unresectable or metastatic
cholangiocarcinoma (CCA) and other solid tumors. The study consists of 3 parts: a dose
escalation (Part 1), a dose expansion (Part 2), and an extension (Part 3).

Eligibility

  1. Histologically or cytologically confirmed unresectable or metastatic solid tumor
  2. Documented FGFR2 gene fusion, mutation, or amplification per local testing of blood and/or tumor
  3. Patient must have measurable disease per RECIST v1.1
  4. Patient has ECOG performance status of 0-1
  5. Patient must have disease that is refractory to standard therapy, disease that has not adequately responded to standard therapy, disease for which standard or curative therapy does not exist, or the patient must be intolerant to or have declined standard therapy
  6. Part 2 dose expansion patients with Cholangiocarcinoma:
  7. Group 1: CCA patients with an FGFR2 fusion previously treated with an FGFRi
  8. Group 2: CCA patients with an FGFR2 fusion with prior chemotherapy but not previously treated with an FGFRi
  9. Group 6: CCA patients with an FGFR2 fusion with no prior chemotherapy and not previously treated with an FGFRi. Prior adjuvant/neo-adjuvant treatment completed >6 months before enrollment is acceptable. Up to 2 cycles of palliative chemotherapy are allowed during screening
  10. Group 7: CCA patients with an FGFR2 mutation or amplification and not previously treated with an FGFRi. Note: For Group 7, patients with confirmed diagnosis of unresectable or metastatic CCA with an FGFR2 fusion are not eligible.
  11. Part 2 dose expansion patients with other solid tumors (NOT Cholangiocarcinoma):
  12. Group 3: Non-CCA patients with an FGFR2 fusion and not previously treated with an FGFRi.
  13. Group 4: Non-CCA patients with an FGFR2 amplification and not previously treated with an FGFRi.
  14. Group 5: Non-CCA patients with an FGFR2 mutation and not previously treated with an FGFRi
  15. Part 3 extension:
  16. CCA patients with an FGFR2 fusion with prior chemotherapy but not previously treated with an FGFRi

Treatment Sites in Georgia

Winship Cancer Institute of Emory University


1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.